Gupta R K, Morton D L
John Wayne Cancer Institute, Saint John's Hospital and Health Center, Santa Monica, California 90404.
Dis Markers. 1994 Oct;12(1):51-61. doi: 10.1155/1994/756465.
An ELISA to detect a glycoprotein TAA-specific immune complexe (IC) has been developed utilizing a murine monoclonal antibody, AD1-40F4, that recognizes a 90kD subunit of the antigen. In this study we determined the applicability of the assay to assess the presence of the glycoprotein TAA-IC in lung cancer patients. The incidence of glycoprotein TAA-IC was 63% (33/89), significantly higher (p < 0.05) than normal controls (3.2%; 8/250). Comparative analyses of pre- and post-operative sera of non-small cell lung cancer patients revealed that in 30% (20/66) of patients, the ELISA value for the marker did not become negative, i.e., decrease below the cut-off level (0.410 ODnm) after surgical resection of the tumor. It is postulated that these patients either had extensive disease or microscopic metastases that were not resectable. Evaluation of post-operative glycoprotein TAA-IC results in relation to disease recurrence revealed a significant association between the presence of the antigen in serum and disease recurrence. There did not appear to be any association between the glycoprotein TAA-IC and the other conventional marker, CEA; however, using more than one marker increases the incidence of detection of the disease.
利用一种鼠单克隆抗体AD1 - 40F4开发了一种用于检测糖蛋白肿瘤相关抗原（TAA）特异性免疫复合物（IC）的酶联免疫吸附测定（ELISA），该抗体可识别该抗原的一个90kD亚基。在本研究中，我们确定了该检测方法在评估肺癌患者中糖蛋白TAA - IC存在情况的适用性。糖蛋白TAA - IC的发生率为63%（33/89），显著高于正常对照组（3.2%；8/250）（p < 0.05）。对非小细胞肺癌患者术前和术后血清的比较分析显示，在30%（20/66）的患者中，该标志物的ELISA值在肿瘤手术切除后未变为阴性，即未降至临界值水平（0.410 ODnm）以下。据推测，这些患者要么患有广泛性疾病，要么存在不可切除的微小转移灶。对术后糖蛋白TAA - IC结果与疾病复发情况的评估显示，血清中该抗原的存在与疾病复发之间存在显著关联。糖蛋白TAA - IC与另一种传统标志物癌胚抗原（CEA）之间似乎没有任何关联；然而，使用多种标志物可提高疾病的检测率。
